Sun Pharma reports positive results from Phase 3 trials for ILUMYA
The studies, named INSPIRE-1 and INSPIRE-2, tested ILUMYA over a 24-week period. Patients who received ILUMYA showed significant improvements in symptoms of psoriatic arthritis compared to those who received a placebo. Both trials successfully met their primary goal—a higher proportion of patients treated with ILUMYA achieved ACR20 responses, a standard measure used to assess improvement in joint disease, by Week 24. The results were statistically significant.
On the safety front, the drug performed as expected. There were no new safety concerns, and the data remained in line with ILUMYA's existing safety record. The drug is already approved to treat moderate-to-severe plaque psoriasis, and these latest findings suggest it may have potential in addressing PsA as well.
However, it's important to note that ILUMYA is not yet approved for psoriatic arthritis, and its use for this indication has not been reviewed or authorized by health regulators.
Marek Honczarenko, MD, PhD, Senior Vice President and Head of Global Specialty Development at Sun Pharma, stated, 'We are excited to share that both the INSPIRE-1 and INSPIRE-2 clinical trials have successfully met their primary endpoints. These top-line results reinforce the therapeutic potential of ILUMYA as a treatment option for patients with active psoriatic arthritis. We extend our sincere gratitude to the patients, healthcare professionals and administrators whose contributions made the studies possible. We look forward to sharing the complete clinical data in the near future.'
Sun Pharma plans to present the full results from these studies at upcoming medical conferences and publish them in peer-reviewed journals.
Ahmedabad Plane Crash
Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at BusinessUpturn.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Weight-loss jabs could minimise the symptoms of asthma
Weight-loss jabs could help minimise asthma symptoms in obese people, according to a study. The drugs should be explored as a potential treatment for obese people with the respiratory condition, who are 'often resistant' to steroids, researchers said. Weight-loss jabs, also known as glucagon-like peptide1 receptor-agonists (GLP1-RAs), work by mimicing the hormone GLP-1 to regulate blood sugar and insulin levels. They were initially developed as a treatment for people with type 2 diabetes. A number of types of the drug are recommended to help tackle obesity on the NHS, including semaglutide, or Wegovy, and tirzepatide, or Mounjaro. Previous studies have suggested the drugs may slash the risk of illnesses like dementia and stroke, with an international team of experts exploring their potential impact on obese people with asthma. Professor David Price, University of Aberdeen chair in primary care respiratory medicine, said: 'People with obesity and asthma are unique in that they are often resistant to steroid treatments. READ MORE: Brits issued drink warning at popular Mediterranean holiday spot READ MORE: Gran banned from Asda after being accused of swapping yellow stickers 'We know that GLP1s work on inflammatory responses in the airways in a different way to traditionally used steroids.' For the study, published in Advances in Therapy, researchers analysed the records of 10,111 people on GLP1-RAs and 50,555 people who were not on the drugs. After a follow-up period, the team found that those taking weight-loss jabs lost more weight and had improved asthma control. Researchers said the findings suggest medics 'should pay attention to the relationship between GLP-1 RA and the risk of respiratory diseases'. Prof Price added: 'We found compelling evidence that GLP1s, as well as increasing weight loss, also improved asthma symptoms. In addition, it is important to note that the benefits to asthma symptoms occurred despite fairly modest weight loss of around 0.9kg over the course of the year. 'Our findings suggest that GLP1s may have beneficial effects on asthma control for people with obesity and this should be explored further.' Prof Alan Kaplan, chairperson of the Family Physician Airways Group of Canada and the Observational and Pragmatic Research Institute, said: 'Our findings suggest that GLP1-RAs have benefits on asthma control in people with obesity, and this information should contribute to the discussions around the decision to use these drugs.' Dr Erika Kennington, head of research and innovation at Asthma and Lung UK, said: 'Research has previously shown that people living with obesity who lose weight see improved control of their asthma, so it's encouraging to see this study show this is still the case when the weight loss is driven by drugs, like the new class of weight loss drugs. 'Although exercise can help people lose weight, for some people it can cause anxiety about becoming breathless or having an asthma attack, so people are stuck in a vicious cycle of not being able to lose weight and their asthma worsening. Therefore, where exercise hasn't worked for someone these drugs that support weight loss could offer a promising alternative. 'It's too early to say whether these drugs would be effective for people with asthma more widely. More research is needed to understand how these drugs actually improve asthma control. Funding for lung health research is on life support and urgent action is needed to increase investment.'
Associated Press
an hour ago
- Associated Press
Gilead Receives Positive CHMP Opinions Under Accelerated Review From European Medicines Agency for Twice-Yearly Lenacapavir for HIV Prevention
FOSTER CITY, Calif.--(BUSINESS WIRE)--Jul 25, 2025-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion under accelerated review recommending lenacapavir—the company's injectable HIV-1 capsid inhibitor—for use as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults and adolescents with increased HIV-1 acquisition risk. The final European Commission (EC) decision is expected later this year, and, if approved, lenacapavir will be marketed in the European Union (EU) under the trade name Yeytuo ®. The marketing authorization application (MAA) recommendation will now be reviewed by the EC as it evaluates lenacapavir as a potential new preventative strategy against HIV in all 27 EU Member States, as well as Norway, Iceland and Liechtenstein. Additionally, if approved, lenacapavir will be granted one additional year of market exclusivity in the EU as a result of the new indication. The CHMP also adopted a positive EU-Medicines for all (EU-M4all) opinion, which enables a streamlined assessment for World Health Organization (WHO) prequalification and will facilitate national regulatory evaluations in low- and lower-middle-income countries (LLMICs). 'This milestone reflects our commitment to reimagine HIV prevention in Europe and around the world,' said Dietmar Berger, MD, PhD, Chief Medical Officer at Gilead Sciences. 'Lenacapavir for PrEP has the potential to become a critical tool for public health, helping to expand prevention options for people who face the highest barriers to care.' Despite ongoing advances in HIV prevention, persistent social and economic factors including stigma and discrimination continue to cause disparities in PrEP use. In 2023, a total of 24,731 new HIV diagnoses were reported across 30 EU/European Economic Area countries—an increase of 11.8% compared with 2022. 'These positive opinions from the CHMP are an important step toward a new HIV prevention option that could help meet the diverse needs of people across Europe and aim at helping end new HIV infections by the EU target of 2030,' said Jean-Michel Molina, MD, PhD, Université Paris Cité, Professor of Infectious Diseases and Head of the Infectious Diseases Department at the Saint-Louis and Lariboisière Hospitals. 'The opinions reflect the strength of the clinical evidence and the potential of long-acting innovations like lenacapavir to address real-world barriers to the use of PrEP. Expanding the range of PrEP options, in Europe and in countries around the world, is essential to making HIV prevention more accessible for people who need it most.' The positive opinions were supported by data from the Phase 3 PURPOSE 1 and PURPOSE 2 trials conducted by Gilead. In the PURPOSE 1 trial ( NCT04994509 ), data at the primary analysis showed that administration of twice-yearly subcutaneous lenacapavir led to zero HIV infections among 2,134 participants, 100% reduction in HIV infections and superiority of prevention of HIV infections when compared with once-daily oral Truvada ® (emtricitabine 200mg and tenofovir disoproxil fumarate 300mg; F/TDF) in cisgender women in sub-Saharan Africa. In the PURPOSE 2 trial ( NCT04925752 ), there were two HIV infections among 2,179 participants in the twice-yearly subcutaneous lenacapavir group, demonstrating 99.9% of participants did not acquire HIV infection and superiority of prevention of HIV infections when compared with once-daily oral Truvada among a broad and geographically diverse range of cisgender men and gender-diverse people. In both trials, lenacapavir demonstrated superiority of prevention of HIV infections when compared with background HIV incidence (bHIV) and was generally well-tolerated, with no significant or new safety concerns identified . Data from both trials were published in The New England Journal of Medicine and, based in part on the trial results, in December 2024 the journal Science named lenacapavir its 2024 'Breakthrough of the Year.' Continued Global Regulatory Filings for Lenacapavir for HIV Prevention, Milestone Partnerships and Global Guidance Gilead is executing a global access strategy informed by health advocates and organizations that prioritizes speed and enables the most efficient paths for regulatory review, approval of and access to twice-yearly lenacapavir for PrEP. More information about Gilead's recently announced strategic partnership agreement with The Global Fund to Fight AIDS, Tuberculosis and Malaria, as well as updates on Gilead's access strategies in countries and regions around the world: See Gilead press release More information about the WHO's recently announced guidelines for the use of lenacapavir for PrEP: See Gilead company statement Lenacapavir for PrEP is not approved by any regulatory authority outside of the United States. There is currently no cure for HIV or AIDS. About the PURPOSE Program Gilead's landmark PURPOSE program is the most comprehensive and diverse HIV prevention trial program ever conducted. The program comprises five HIV prevention trials around the world that are focused on innovation in science, trial design, community engagement and health equity. The PURPOSE trials are evaluating the safety and efficacy of an investigational, twice-yearly injectable medicine, lenacapavir, to reduce the chance of getting HIV. The Phase 2 and 3 program, consisting of PURPOSE 1-5, is assessing the potential of lenacapavir to help a diverse range of people around the world who could benefit from PrEP. More information about the PURPOSE program, including individual trial descriptions, populations and locations, can be found at About Lenacapavir Lenacapavir is approved in multiple countries for the treatment of multi-drug-resistant HIV in adults, in combination with other antiretrovirals. Lenacapavir is also approved in the United States to reduce the risk of sexually acquired HIV in adults and adolescents (≥35kg) who are at risk of HIV acquisition. The multi-stage mechanism of action of lenacapavir is distinguishable from other currently approved classes of antiviral agents. While most antivirals act on just one stage of viral replication, lenacapavir is designed to inhibit HIV at multiple stages of its lifecycle and has no known cross resistance exhibited in vitro to other existing drug classes. Lenacapavir is being evaluated as a long-acting option in multiple ongoing and planned early and late-stage clinical studies in Gilead's HIV prevention and treatment research program. Lenacapavir is being developed as a foundation for potential future HIV therapies with the goal of offering both long-acting oral and injectable options with several dosing frequencies, in combination or as a mono agent, that help address individual needs and preferences of people and communities affected by HIV. The journal Science named lenacapavir its 2024 'Breakthrough of the Year.' U.S. Indication for Yeztugo® Yeztugo (lenacapavir) injection, 463.5 mg/1.5 mL, is indicated for pre‑exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults and adolescents (≥35kg) who are at risk for HIV-1 acquisition. Individuals must have a negative HIV-1 test prior to initiating Yeztugo. U.S. Important Safety Information for Yeztugo BOXED WARNING: RISK OF DRUG RESISTANCE WITH USE OF YEZTUGO IN UNDIAGNOSED HIV-1 INFECTION Contraindications Warnings and precautions Adverse reactions Drug interactions Dosage and administration About Gilead HIV For more than 35 years, Gilead has been a leading innovator in the field of HIV, driving advances in treatment, prevention and cure research. Gilead researchers have developed 13 HIV medications, including the first single-tablet regimen to treat HIV, the first antiretroviral for pre-exposure prophylaxis (PrEP) to help reduce new HIV infections, and the first long-acting injectable HIV treatment medication administered twice-yearly. Our advances in medical research have helped to transform HIV into a treatable, preventable, chronic condition for millions of people. Gilead is committed to continued scientific innovation to provide solutions for the evolving needs of people affected by HIV around the world. Through partnerships, collaborations and charitable giving, the company also aims to improve education, expand access and address barriers to care, with the goal of ending the HIV epidemic for everyone, everywhere. Gilead was recognized as one of the leading philanthropic funders of HIV-related programs in a report released by Funders Concerned About AIDS. About Gilead Sciences Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer and inflammation. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California. Forward-Looking Statements This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including Gilead's ability to initiate, progress and complete clinical trials in the anticipated timelines or at all, and the possibility of unfavorable results from ongoing and additional clinical trials, including those involving Yeztugo (lenacapavir) (such as PURPOSE 1 and PURPOSE 2); uncertainties relating to regulatory applications and related filing and approval timelines, including regulatory applications for lenacapavir for PrEP, and the risk that any regulatory approvals, if granted, may be subject to significant limitations on use or subject to withdrawal or other adverse actions by the applicable regulatory authority; the possibility that Gilead may make a strategic decision to discontinue development of lenacapavir for indications currently under evaluation and, as a result, lenacapavir may never be successfully commercialized for such indications; Gilead's ability to effectively manage the access strategy relating to lenacapavir, subject to necessary regulatory approvals; and any assumptions underlying any of the foregoing. These and other risks, uncertainties and factors are described in detail in Gilead's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, as filed with the U.S. Securities and Exchange Commission. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The reader is cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and is cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation and disclaims any intent to update any such forward-looking statements. U.S. full Prescribing Information for Truvada and Yeztugo, including Boxed Warning, are available Truvada, Truvada for PrEP, Yeztugo, Yeytuo, Gilead and the Gilead logo are registered trademarks of Gilead Sciences, Inc., or its related companies. For more information about Gilead, please visit the company's website follow Gilead on X/Twitter (@Gilead Sciences) and LinkedIn (@Gilead-Sciences). View source version on CONTACT: Ashleigh Koss, Media [email protected] Ross, Investors [email protected] KEYWORD: EUROPE UNITED STATES NORTH AMERICA CALIFORNIA INDUSTRY KEYWORD: AIDS HEALTH INFECTIOUS DISEASES HOSPITALS PHARMACEUTICAL BIOTECHNOLOGY SOURCE: Gilead Sciences, Inc. Copyright Business Wire 2025. PUB: 07/25/2025 03:00 AM/DISC: 07/25/2025 03:01 AM
Yahoo
an hour ago
- Yahoo
My doctor shamed me when I asked about weight loss drugs. But they've helped me lose 80 pounds and stop binge eating.
"Yay science." For years, Elyse Schroeder had a secret routine. She would wake up with constant thoughts of food playing on loop in her mind. Schroeder would deny her cravings, delaying her first bites as long as she could in an effort to limit her daily calorie intake. But once she was alone, the binging would begin. 'The second my kids would go to school, I would be eating,' she tells Yahoo. 'I would go get fast food and hide the evidence at the bottom of the garbage — there was this cycle of shame that I couldn't get control of.' But not for lack of trying. Schroeder says she tried 'every fad diet that exists.' She joined gyms and worked with dietitians. It would work, for a while, and she would lose some weight. Ultimately, however, 'I couldn't get over the obsession with food, and eventually I would undo every good choice I had made,' she says. 'I couldn't get control of my disordered eating.' She was desperate not to pass her toxic relationship with food onto her children, and knew that diets weren't the solution. Then, the 39-year-old content creator and social media marketing specialist saw people talking about GLP-1 weight loss medications on TikTok. After finding out she was prediabetic, Schroeder asked her doctor about the drugs. 'Her verbatim words were 'I don't believe in those medications, and I really think we can help you with diet and exercise'' — the same ineffective methods Schroeder had tried for years. 'She didn't help me, she shamed me,' says Schroeder. So she struck out on her own to get compounded tirzepatide. Over the course of two years on the medication, Schroeder has lost more than 80 pounds and restored her relationship with food. When she met with a new doctor, 'The first thing she said to me was, 'I hope you are so proud of yourself,'' says Schroeder. 'I burst into tears.' And she is proud of herself, not because of the weight loss but because 'I feel so at peace with my life and where I am in my relationship with food,' she says. For this edition of Yahoo's On My Weigh series, Schroeder shares in her own words all the positive changes 'one little weekly injection has brought' to her life: 'Yay science!' The Weigh-in Name: Elyse Schroeder Age: 39 The method: Compounded tirzepatide, 12.5 milligrams The goal: Before I started tirzepatide, I had bloodwork done, and my doctor told me I was prediabetic. So when I decided to try the medication, truly my only goal was to get my bloodwork back to normal. I didn't care about losing weight, though I hoped I might. As a mom of three kids, I didn't want to die early or to pass on my disordered eating to them. I was 220 pounds when I took my first dose of tirzepatide, and I was just trying to get under 190 pounds. That's not even a healthy body mass index (BMI) for me, but I didn't think I'd be able to lose more than that. Progress report card: I couldn't even tell you the last time I've had an episode of binge eating. It's definitely been at least a year. I eat when it's time to eat, not to soothe myself. My blood work is passed-with-flying-colors stellar. My doctor is so happy. I go to the gym four to five times a week, happily. Once I surpassed my 190-pound goal, my new goal weight became 150 pounds. After I hit that, my doctor suggested that, because of my relationship with food, we should focus on my body fat percentage, rather than weight. My body fat has decreased, and my muscle mass has increased. I now bounce between 138 and 140 pounds, but I don't really care because I'm focused on being strong and healthy. Food noise volume: Before tirzepatide, my food noise volume was at a 10. I would be eating and thinking about what I was going to eat after that. I would force myself to go to sleep early just to stop thinking about food. It was all-consuming. And there was so much shame that went along with that: Why can't I feel full or pack up leftovers like other people? I thought it was an issue of self-control or motivation, but now that I have the medication, I realize that my brain handles food noise differently than that of a person without the disease of obesity. Now, my food noise volume is at about a 3. I basically only experience it when I'm hungry! Day in the Life Rise and shine Before taking tirzepatide, I felt like a slug. It was so hard getting my body out of bed, and I didn't feel excited for the day. I would just think, Another day of struggling, of self-loathing, of wondering why I can't fix this. My sleep and morning mood have been so affected by tirzepatide. I wake up excited and ready for the day. I love a good cup of coffee, but often I don't even really need it in the morning. I just drink it because it's yummy. And I look forward to going to the gym first thing in the morning now. If you told the old me that the gym would become one of my favorite parts of the day, I would've been like, 'You're high.' First bites I used to try to delay breakfast and starve myself in the morning, thinking I would eat fewer calories that way. But I've learned that that was dumb because then I'd get to Starbucks after my kids went to school, and my brain would be in this ravished state. I'd get their double-smoked bacon, cheddar and egg sandwich. Honestly, that sandwich still slaps, but it's just two flimsy pieces of bacon, so it's really not doing that much protein- and nutrition-wise. Despite trying so many diets, my knowledge of nutrition before tirzepatide was really not great. I thought protein came from peanut butter, the end. Now, I eat a very protein-heavy diet. I start my day with a protein shake of some sort while I'm getting the kids ready for school and before I head to the gym. When I get home, I usually make some eggs with some fruit and maybe some sausage. I'm a creature of habit and, as long as I'm not sick of eating it, having the same thing every day eliminates the stress of coming up with something new. Get ready with me Before starting tirzepatide, I truly had like five outfits. I thought there was no point in spending money on clothes when I didn't like how anything looked on me. Now, to my husband's dismay, I love getting dressed and buying new clothes. When you can fit in anything that feels exciting to you, it's fun to get dressed. I used to only wear black, but now in the morning I get to ask what colors I want to wear today — and sometimes it's bright pink. I love doing my makeup and hair now too. It feels like I love myself enough to get ready. Make a move I'm now an Orangetheory girlie, and I like to go to the 7:15 a.m. class, because if I don't do it in the morning, my body says 'no' to the gym. I love the mixture of cardio and lifting weights on the floor. I never thought I would like lifting weights, but now I'm starting to see definition, which is exciting, and I just really enjoy it. I waited until about a month before I entered my maintenance phase (and was no longer trying to lose more weight) to start going to the gym. Orangetheory is really hard, even at a healthy weight — it would have really hurt when I was carrying 80 additional pounds. And I didn't feel like I belonged there. I imagined everyone would think, Oh, there's the fat girl, trying to lose weight … what did she eat before this? Earlier on in my journey, I told myself that any movement is good movement, so I walked every day with my dog for at least 30 minutes. And then one morning — maybe because it was winter and cold in Wisconsin — I just woke up and decided to try Orangetheory. I was so scared to go to my first class, because I had no idea what to do in a gym. But the structure of Orangetheory — where someone is like, 'Here's how you hold a weight, here's how you lift it, now do it 10 times' — has been great for me. Dose time For the first six months I was taking it, I had pretty much all of the side effects of tirzepatide, except constipation and vomiting (though I tried semaglutide a year before tirzepatide, and it made me throw up so much I quit after three shots). So I had to make sure I got plenty of electrolytes and ate very clean and protein-heavy the day before I took my injection. And I started taking psyllium husk to help with diarrhea. I always try to take it in the morning, so that I have the rest of the day to recover if my tummy is a little wonky. If I try to take it in the afternoon or evening, I just wake up feeling a little hungover and uneasy the next day. Since entering the maintenance phase in March, I'm a little more flexible on my shot schedule. Sometimes I wait nine or 10 days to take it instead of a week, if I hit day 7 and don't feel like my food noise is coming back. I typically take my shot on Tuesdays. That way, when the weekend comes, if I decide to have a glass of wine, it doesn't upset my tummy. I don't really get side effects now, except that I'm cold a lot, and like some others on GLP-1s, I get a little allodynia, a kind of skin sensitivity that makes it feel like I have a mild sunburn on the backs of my arms or legs. But it's all manageable, and I've never considered quitting tirzepatide. Let's do lunch Lunch before tirzepatide was always some kind of packaged or fast food. And I would overeat at lunch, feel like crap and need a nap every single day. I'll admit: I don't love cooking. It stresses me out because I can't forward-plan. But my husband is the best. He meal preps for me so my lunch is set to go. I love the salads and wraps he makes me. My current fixation is his Mediterranean bowls with chicken, rice, hummus, olives, pita — I could eat them every day! It's crazy how much my cravings have changed. I wanted burgers and fries; now I really crave protein and fruit and veggies. I never craved stuff like that before. Happy hour Happy hours and social outings used to be such a point of stress for me when I was doing these very rigid diets, like Whole30, paleo and WeightWatchers. I wouldn't want to go to happy hour because I knew that that would be a free-for-all where I would want to over-consume food and alcohol. I can be honest about it now that I'm on the other side: I was drinking too much before I started taking tirzepatide. I really wanted to be free from all the shame and worry I felt in social settings. Now, with the medication, those things don't stress me out at all. I know that the medication will naturally moderate how much I take in. I have about a glass of wine a month. I know I'm not going to eat healthily like I do at home when I go to these events, and that's OK. I can lean into it now and have fun and know that tomorrow I'm going to go back to my routine. Before, it felt like every outing meant I was falling off the wagon and had to start over again. These days, going out feels stress-free. Plus, being on weight loss medication has opened up a whole new world of outdoor activities I do with my family. Before, my husband would take the kids for a hike on a weekend afternoon. I would stay home and take a nap. I didn't feel like I could keep up, and it didn't sound fun. Now I'm the one planning hikes. We just got back from the Badlands in South Dakota, where we were hiking and climbing for days, and it was so much fun! Before tirzepatide, that would've sounded like torture to me. It makes me sad to think about the things I chose not to participate in and how much I missed out on when my kids were little because I just didn't have the energy to do things with them. Dinner bell One of my favorite things about this process is how dinner has changed: My whole family eats at the table together. It's difficult now that the kids are at the age of after-school activities, but it's important. In the era of my crash dieting, I was always eating something different from them because I had been 'bad' during the day, so I felt like I had to undo the damage. What message was that sending to the kids, that I couldn't eat what they were eating? Now that my kids are older, it's so important for them to have a healthy relationship with food. I want them to understand that just because I'm a woman, that doesn't mean I need to only eat leaves. I don't want to put a thought in their heads that they have to diet, which is part of why, for the time being, they don't know that I'm taking weight loss medications. Now, we all eat the same thing. Often, that's something nutritious that my husband cooked on the grill. My daughter loves to make salad; she calls it 'her specialty.' So we'll have a salad she made, some vegetables and some kind of carb. And sometimes we have a frozen pizza — and that's OK. Let's get the bill I'm telling you, if I had to get a second job to make enough money to pay for this medication, I would do it in a heartbeat. I pay for a $79-a-month membership to my telehealth provider, and it's $99 for a month's supply of tirzepatide, no matter what the dose. When I think about how much I used to spend on groceries and drive-throughs — it was just so much food — it was insane. My husband and I laugh now because we'll put together an Instacart order and he'll be like, 'This total is so low!' And it's because I'm not ordering 12 bags of Doritos; that's expensive! Yes, produce and whole foods are expensive too, but I'm eating a normal amount now. So, I feel like, financially, it all comes out in the wash now. Solve the daily Crossword
